Skip to main content
. 2022 Feb 24;14(5):1168. doi: 10.3390/cancers14051168

Figure 3.

Figure 3

PFS and OS analysis of ramucirumab 12 mg/kg plus paclitaxel in JVCZ versus placebo plus paclitaxel in RAINBOW (Analysis 1) and 12 mg/kg versus 8 mg/kg within JVCZ (Analysis 2) (A), PFS (B), and OS (C). Abbreviations: OS—overall survival; PFS—progression-free survival.